ClinicalTrials.gg

Program

inavolisib

Also written as “Inavolisib”, “Inavolisib (Dose #1)” and “Inavolisib (Dose #2)”.

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Neoplasms · Prostatic Neoplasms · Neoplasm Metastasis, led by Hoffmann-La Roche.

Furthest: phase 3, since Dec 2, 201920 company-led studies, 17 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche2017 open or runningphase 3since Dec 2, 2019Dec 22, 2016Dec 31, 2026phase 1 · NCT03006172

Also a collaborator on its studies: Gilead Sciences and Pfizer.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Dec 22, 2016.

  1. Mar 15, 2021Phase 2 study in Neoplasm MetastasisNCT04802759 · 316 planned · United States, Australia, Israel and more
  2. Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more
  3. Jun 11, 2021Phase 1 study in Colorectal NeoplasmsNCT04929223 · 542 planned · United States, Australia, Canada and more
  4. Dec 2, 2022Phase 3 study in Breast NeoplasmsNCT05646862 · 420 planned · United States, Argentina, Australia and more
  5. May 1, 20232 phase 3 studiesNCT05862285, NCT05894239
  6. Jul 4, 2024Phase 1 study in PIK3CA-Mutated CancersNCT06496568 · 30 enrolled · United States, Canada, South Korea
  7. Jan 14, 2025Phase 3 study in Breast NeoplasmsNCT06790693 · 450 planned · United States, Argentina, Australia and more
  8. Jun 26, 2025Phase 2 study in Breast NeoplasmsNCT07054190 · 120 planned · United States, Argentina, Brazil and more
  9. Aug 20, 2025Phase 1 study in Hepatic ImpairmentNCT07144111 · 27 enrolled · United States
  10. Dec 11, 2025Phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT07287150 · 100 planned · United States, Australia, Brazil and more
  11. Jan 6, 20262 phase 2 studiesNCT07323576, NCT07368998
  12. Feb 6, 2026Phase 2 study in Breast NeoplasmsNCT07405801 · 80 planned · United States, Argentina, Brazil and more
  13. Jul 20, 2026Phase 2 study in Breast NeoplasmsNCT07748208 · 40 planned · United States, Puerto Rico
  14. Nov 13, 2026Primary completion moved from 2026-12-31 to 2027-05-03Date moved laterphase 3 · +4 months · NCT05894239

Ahead

  1. Nov 13, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT05646862
  2. Dec 31, 2026Primary completion: phase 1 study in Breast NeoplasmsNCT03006172
  3. May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05894239
  4. Jul 21, 2027Primary completion: phase 1 study in PIK3CA-Mutated CancersNCT06496568

TargetBeta

PIK3CA →read by rule
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
AlpelisibruleNovartisphase 437
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07748208Breast Neoplasms · United States, Puerto Rico2RecruitingJun 15, 202940
NCT07405801Breast Neoplasms · United States, Argentina, Brazil and more2RecruitingDec 19, 202880
NCT07368998Breast Neoplasms · United States, Argentina, Australia and more2RecruitingOct 31, 202880
NCT07323576Colorectal Neoplasms2WithdrawnMar 1, 20290
NCT07287150Metastatic Castration-Resistant Prostate Cancer · United States, Australia, Brazil and more2RecruitingMar 31, 2028100
NCT07144111Hepatic Impairment · United States1CompletedOct 13, 202627
NCT07054190Breast Neoplasms · United States, Argentina, Brazil and more2RecruitingJul 31, 2027120
NCT06790693Breast Neoplasms · United States, Argentina, Australia and more3RecruitingJan 31, 2032450
NCT06496568PIK3CA-Mutated Cancers · United States, Canada, South Korea1Active, not recruitingJul 21, 202730
NCT05894239Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMay 3, 2027230
NCT05862285Neoplasms · Belgium, Canada, China and more3RecruitingMar 1, 2033200
NCT05646862Breast Neoplasms · United States, Argentina, Australia and more3RecruitingNov 13, 2026420
NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more1RecruitingAug 31, 2030542
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingFeb 28, 2028176
NCT04802759Neoplasm Metastasis · United States, Australia, Israel and more2RecruitingMay 30, 2029316
NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States2CompletedDec 4, 2023252
NCT04589845Solid Tumors · United States, Australia, Belgium and more2Active, not recruitingSep 25, 2032920
NCT04191499Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingSep 29, 2023325
NCT03424005Breast Neoplasms · United States, Australia, France and more2RecruitingSep 30, 20301,132
NCT03006172Breast Neoplasms · United States, Canada, France and more1Active, not recruitingDec 31, 2026200

How it is read

Names in the registry

  • “Inavolisib”, 20 entries
  • “Inavolisib (Dose #1)”, 1 entry
  • “Inavolisib (Dose #2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.